back

Trastuzumab deruxtecan (new indication: gastric or gastroesophageal junction (GEJ) adenocarcinoma; HER2-positive; after a trastuzumab-based regimen)

 

Subject:

  • Active Substance: Trastuzumab deruxtecan
  • Name: Enhertu®
  • Therapeutic area: Gastric or gastroesophageal junction (GEJ) adenocarcinoma
  • Pharmaceutical company: Daiichi Sankyo Deutschland GmbH

 

Time table:

  • Start: 01.02.2023
  • Final decision by G-BA: 20.07.2023

 

Final decision:

  1. After prior first-line trastuzumab-based first-line therapy: No additional benefit proved
  2. After at least two prior treatment regimens, including trastuzumab: No additional benefit proved